The pan-PI3K inhibitor, GDC-0941, resulted in arrest of all peripheral and cutaneous T-cell lymphoma cell lines in the G1 phase. Here, PIK3CD is linked to primary cutaneous T-cell non-Hodgkin lymphoma.